1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti–topoisomerase I antibody
Article first published online: 30 JUL 2007
DOI: 10.1002/art.22747
Copyright © 2007 by the American College of Rheumatology
Additional Information
How to Cite
Perera, A., Fertig, N., Lucas, M., Rodriguez-Reyna, T. S., Hu, P., Steen, V. D. and Medsger, T. A. (2007), Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti–topoisomerase I antibody. Arthritis & Rheumatism, 56: 2740–2746. doi: 10.1002/art.22747
Publication History
- Issue published online: 30 JUL 2007
- Article first published online: 30 JUL 2007
- Manuscript Accepted: 17 APR 2007
- Manuscript Received: 15 AUG 2006
Funded by
- Shoemaker Fund of the Western Pennsylvania Chapter of the Arthritis Foundation
- Scleroderma Research Foundation, Richmond, Massachusetts
- RGK Foundation, Austin, Texas
- Scleroderma Foundation, Peabody, Massachusetts
- Taub Fund, Chicago, Illinois
- NIH. Grant Number: 5M01-RR-00056
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling, Expert Review of Clinical Immunology, 2011, 7, 4, 463
- 2, , , Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons, International Journal of Clinical Rheumatology, 2011, 6, 2, 219
- 3, , , , , , GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production, Arthritis & Rheumatism, 2011, 63, 6Direct Link:
- 4, , , , , , The correlation between durometer score and modified Rodnan skin score in systemic sclerosis, Rheumatology International, 2011,
- 5
- 6
- 7
- 8
- 9
- 10, , , , Heart involvement in systemic sclerosis: Evolving concept and diagnostic methodologies, Archives of Cardiovascular Diseases, 2010, 103, 1, 46
- 11, , Rheumatic manifestations of skin disease, Current Opinion in Rheumatology, 2010, 22, 1, 78
- 12, , , Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis, Arthritis & Rheumatism, 2009, 60, 4Direct Link:
- 13, , , Genetic susceptibility to systemic sclerosis, European Journal of Internal Medicine, 2009, 20, 3, 242
- 14, , , , , , , , Induction of interferon-α by scleroderma sera containing autoantibodies to topoisomerase I: Association of higher interferon-α activity with lung fibrosis, Arthritis & Rheumatism, 2008, 58, 7Direct Link:
- 15, , , Predictive value of antinuclear autoantibodies: The lessons of the systemic sclerosis autoantibodies, Autoimmunity Reviews, 2008, 7, 8, 588
- 16, , , Sclérodermie systémique : état des lieux en 2008, Revue du Rhumatisme, 2008, 75, 10-11, 918
- 17, , , Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies, Current Opinion in Rheumatology, 2008, 20, 6, 697
- 18
- 19
- 20, , Risikoadaptierte Therapien bei der systemischen Sklerose, Zeitschrift für Rheumatologie, 2007, 66, 8, 672